Rapid weight loss has many possible outcomes
They each come in multiple dose strengths
These findings are confirmed in clinical practice and align with what patients report when consistency is maintained
"FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list." 2026
Rather than pursuing unproven combinations of investigational and licensed agents, patients are encouraged to: Engage with NHS weight management services , which offer multidisciplinary support including dietary advice, behavioural therapy, and pharmacotherapy where appropriate including orlistat and, where eligible, GLP-1-based medicines Discuss licensed options with their GP if they meet eligibility criteria, including referral pathways for bariatric surgery in line with NICE obesity guidance Participate in clinical trials if interested in investigational agents such as retatrutide, through legitimate research pathways listed on the NIHR Clinical Research Network or ClinicalTrials.gov The safest and most effective treatments are those supported by robust clinical evidence, prescribed by qualified clinicians, and obtained through regulated supply chains
